December 17, 2004 -- COX-2 inhibitors are not as different as it once appeared. A government-sponsored trial of Pfizer’s Celebrex was halted today because patients taking Celebrex had 2.5 times as many heart attacks as patients taking placebo. It now seems that the whole COX-2 class is dead. Will this setback be as devastating for Prizer as Vioxx was for Merck? We weigh in with our assessment...
